Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

21. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} One RCT of adalimumab and one RCT of dexamethasone showed significant benefits over placebo in adults with active non-infectious posterior-segment uveitis, but there is uncertainty around cost-effectiveness of both drugs. {{author}} {{($index , , , , , , , , & . Hazel Squires 1

NIHR HTA programme2017

22. Adalimumab (Humira) - for the treatment of paediatric chronic non-infectious anterior uveitis

Adalimumab (Humira) - for the treatment of paediatric chronic non-infectious anterior uveitis Final Appraisal Recommendation Advice No: 2717 – December 2017 Adalimumab (Humira ® ) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial) Limited submission by AbbVie Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. • The Summary of Product Characteristics recommends that paediatric uveitis patients are treated (...) with adalimumab in combination with methotrexate. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3035), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has

All Wales Medicines Strategy Group2017

23. Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis

Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User (...) Password Log in × Reset password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × September 2017. Volume 13. Number 3 Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email

Evidencias en Pediatría2017

24. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Adalimumab, etanercept and ustekinumab all offer some benefits for plaque psoriasis in children and young people but their cost per QALY is highly uncertain. {{author}} {{($index , , , , , , , & . Ana Duarte 1 , Teumzghi Mebrahtu 2 , Pedro Saramago Goncalves 1 , Melissa Harden 2 , Ruth Murphy 3 , Stephen Palmer 1 , Nerys Woolacott 2

NIHR HTA programme2017

25. Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica

Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica Journals Library An error occurred retrieving content to display, please

NIHR HTA programme2017

26. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs). METHODS: In this 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial, we randomly assigned (...) patients in a 2:2:2:1:1 ratio to receive one of the following regimens: tofacitinib at a 5-mg dose taken orally twice daily (107 patients), tofacitinib at a 10-mg dose taken orally twice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), placebo with a blinded switch to the 5-mg tofacitinib dose at 3 months (52), or placebo with a blinded switch to the 10-mg tofacitinib dose at 3 months (53). Placebo groups were pooled for analyses up to month 3. Primary end

NEJM2017

27. Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia

Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia 29089788 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia. 181-184 10.2147/OARRR.S142411 The objective of the study was to assess the effectiveness of adalimumab as a treatment for fatigue in patients with rheumatoid arthritis (RA (...) ). Fatigue was monitored in patients with RA who were already on an adalimumab treatment regimen. Fatigue, general well-being, comorbidities, and disease activity were measured at baseline and ~8, 16, and 24 weeks, thereafter. Significant reductions in fatigue scores and disease activity were observed from baseline to 6 months after. A predictive regression model of fatigue severity was proposed and was found to be significant, with RA disease activity as the most significant predictor of fatigue

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

28. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial 28939629 2017 09 23 2017 09 23 1468-2060 2017 Sep 22 Annals of the rheumatic diseases Ann. Rheum. Dis. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. annrheumdis-2017-211781 10.1136/annrheumdis (...) -2017-211781 High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity. Consecutive patients with RA, treated with adalimumab 40 mg every other week for at least 28 weeks, were approached for this randomised, open-label, non-inferiority trial. Patients

EvidenceUpdates2017

29. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment 28900875 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. 391-404 10.1007/s40744-017-0079-x To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA (...) ) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab. All patients discontinued prior adalimumab treatment and continued methotrexate with etanercept 50 mg once weekly for 24 weeks. The primary study endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at week 12. Eighty-five patients (mean age 56.6 years; female 80.0%) were evaluated for safety and 84 for efficacy. Thirty (35.7%) patients achieved ACR20 at week 12

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

30. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study 28798049 2017 08 11 2017 09 06 1468-2060 2017 Aug 10 Annals of the rheumatic diseases Ann. Rheum. Dis. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. annrheumdis-2017-211259 10.1136/annrheumdis-2017-211259 To assess the effect (...) of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

31. Adalimumab (Imraldi) - psoriasis, psoriatic arthritis, axial spondyloarthritis, Crohn?s disease, ulcerative colitis

Adalimumab (Imraldi) - psoriasis, psoriatic arthritis, axial spondyloarthritis, Crohn?s disease, ulcerative colitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 22 June 2017 EMA/CHMP/559383/2017 Committee for Medicinal Products (...) for Human Use (CHMP) Assessment report Imraldi International non-proprietary name: adalimumab Procedure No. EMEA/H/C/004279/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/559383/2017 Page 2/111 Table of contents 1. Background information on the procedure 8 1.1. Submission of the dossier 8 1.2. Steps taken for the assessment of the product 10 2. Scientific discussion 11 2.1. Problem statement 11 2.1.1

European Medicines Agency - EPARs2017

32. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry 28840531 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. 375-389 10.1007/s40744-017-0077-z Current recommendations for the management of rheumatoid arthritis (RA) focus (...) on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients with RA. This study aims to evaluate the long-term (10+ years) persistency and effectiveness of adalimumab in patients with RA in a real-world setting. Included in this study were biologic-naïve adults with RA initiating adalimumab

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

33. Adalimumab and dexamethasone for treating non-infectious uveitis

Adalimumab and dexamethasone for treating non-infectious uveitis Adalimumab and de Adalimumab and dexamethasone for xamethasone for treating non-infectious uv treating non-infectious uveitis eitis T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents 1 Recommendations 4 2 T echnologies 5 3

National Institute for Health and Clinical Excellence - Technology Appraisals2017

34. Adalimumab (Humira) - hidradenitis suppurativa (acne inversa)

Adalimumab (Humira) - hidradenitis suppurativa (acne inversa) Final Appraisal Recommendation Advice No: 1217 – July 2017 Adalimumab (Humira ® ) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial) Limited submission by AbbVie Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3371), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal (...) – 1217: Adalimumab (Humira ® ) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial). July 2017 Recommendation of AWMSG Adalimumab (Humira ® ) is recommended as an option for use within NHS Wales for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. This recommendation applies only in circumstances where the approved

All Wales Medicines Strategy Group2017

35. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison 28762213 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. 349-362 10.1007/s40744-017-0070-6 The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active (...) psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II. To adjust for the cross-trial differences, individual patients in ADEPT were re-weighted so that the mean baseline characteristics

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

36. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Adalimumab, etanercept and Adalimumab, etanercept and ustekinumab for treating plaque psoriasis ustekinumab for treating plaque psoriasis in children and y in children and young people oung people T echnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Technology Appraisals2017

37. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study 28584187 2017 06 06 2017 07 14 1468-2060 2017 Jun 05 Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. annrheumdis-2016-210459 (...) 10.1136/annrheumdis-2016-210459 ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

38. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate (...) , and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate. METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy. Patients were randomly assigned (1:1:1) to receive oral tofacitinib (5 mg twice daily) monotherapy, oral tofacitinib (5 mg twice daily) plus methotrexate

Lancet2017

39. Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) Published 12 June 2017 Product Update: adalimumab (Humira ® ) 40mg/0.4mL pre-filled syringe and pre-filled pen adalimumab (Humira ® ) 40mg/0.8mL vial for paediatric use SMC No. (1243/17) AbbVie Ltd 05 May 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS (...) Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira ® ) is accepted for use within NHS Scotland. Indication under review: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. SMC has previously accepted adalimumab for the treatment of active moderate to severe HS (acne inversa) in adult patients with an inadequate

Scottish Medicines Consortium2017

40. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes 28339738 2017 03 24 2017 05 26 1462-0332 56 6 2017 Jun 01 Rheumatology (Oxford, England) Rheumatology (Oxford) A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. 973-980 10.1093/rheumatology/kex003

EvidenceUpdates2017